Education
About Us
Working with TipRanks
Follow Us
ValiRx PLC (GB:VAL)
LSE:VAL
VAL Stock Chart & Stats
Day’s Range― - ―
52-Week Range0.38p - 2.37p
Previous CloseN/A
Volume1.58M
Average Volume (3M)2.43M
Market Cap
£1.97M
Enterprise Value-919.90K
Total Cash (Recent Filing)£1.56M
Total Debt (Recent Filing)£11.86K
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Jun 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding374,348,660
10 Day Avg. Volume1,128,986
30 Day Avg. Volume2,427,010
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£0.50Price Target Upside-3.85% Downside
Rating ConsensusHold
Number of Analyst Covering0
ValiRx plc News
VAL FAQ
What was ValiRx PLC’s price range in the past 12 months?
ValiRx PLC lowest share price was 0.38p and its highest was 2.37p in the past 12 months.
What is ValiRx PLC’s market cap?
ValiRx PLC’s market cap is £1.97M.
When is ValiRx PLC’s upcoming earnings report date?
ValiRx PLC’s upcoming earnings report date is Jun 10, 2026 which is in 240 days.
How were ValiRx PLC’s earnings last quarter?
Currently, no data Available
Is ValiRx PLC overvalued?
According to Wall Street analysts ValiRx PLC’s price is currently Overvalued.
Does ValiRx PLC pay dividends?
ValiRx PLC does not currently pay dividends.
What is ValiRx PLC’s EPS estimate?
ValiRx PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ValiRx PLC have?
ValiRx PLC has 374,348,660 shares outstanding.
What happened to ValiRx PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ValiRx PLC?
Currently, no hedge funds are holding shares in GB:VAL
Company Description
ValiRx PLC
ValiRx plc (VAL) is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. The company operates primarily in the pharmaceutical sector, with a core focus on the development of novel therapeutics and diagnostics. ValiRx aims to address unmet medical needs through its proprietary drug candidates and technologies, leveraging its expertise in drug development and clinical trials.
Technical Analysis
Evgen Pharma
―
Nuformix Plc
―
Oxford BioDynamics
―
Cizzle Biotechnology Holdings PLC
―
Fusion Antibodies Plc
―
Options Prices
Currently, No data available
---